Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease

doi:10.21203/rs.3.rs-2046848/v1

Download PDF

Research Article

Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease

https://doi.org/10.21203/rs.3.rs-2046848/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this older preprint version

Read the latest preprint version →

Background

In recent years, a burgeoning body of evidence has pointed to age-related dysfunction in neuronal autophagy as playing a prominent role in neuropathology associated with Alzheimer’s disease (AD). In the present study, we investigated the effects of urolithin A (UA), a metabolite generated from ellagic acid via its metabolism by gut bacteria, as an autophagy activator with potential neuroprotective activity.

Methods

WT and 3xTg-AD mice were administered long-term intermittent dietary supplementation with UA. Following evaluation of spatial learning and memory, associative learning and exploratory behavior, we employed fluorescence-based immunodetection of human Aβ42 + Aβ40 to determine Aβ plaque deposition and quantified Aβ42 in hippocampal and cortical homogenates via sandwich ELISA in 14-months old mice. Using neuronal cell types, we analyzed the effects of UA on the expression of autophagy genes and proteins and on lysosomal acidification. We treated mouse hippocampal cells with Aβ oligomers while inducing autophagy with UA and analyzed Aβ clearance.

Results

UA was found to prevent behavioral deficits in this model. It also decreased the Aβ plaque burden in areas of the hippocampus where these protein deposits are prominent in the model. Interestingly, correlation analyses demonstrate that Aβ plaque burden positively correlates with enhanced spatial memory in 3xTg mice on a control diet but not in those supplemented with UA. In contrast, Aβ42 abundance in cortical and hippocampal homogenates negatively correlate with spatial memory in UA-fed mice. UA was also found to extend lifespan in normal aging mice. Mechanistically, we demonstrate that UA is able to induce autophagy and to increase Aβ clearance in neuronal cell lines.

Conclusions

In summary, our data suggest that plaque formation may be a protective mechanism against neurodegeneration and cognitive decline and that targeting the generation of proteotoxic Aβ species might be a more successful approach in halting disease progression than targeting plaque formation. UA, likely via its actions as a autophagy inducer, is capable of removing Aβ from neurons and its dietary administration prevents the onset of cognitive deficits associated with pathological Aβ deposition the 3xTg AD mouse model as well as extending lifespan in normal aging mice.

Aβ

cognition

Urolithin A

autophagy

lifespan

Alzheimer’s disease (AD) is the most common form of dementia and an increasingly critical public health issue, particularly in countries where life expectancy is higher [1]. The two most well-known neuropathological events that occur during AD pathogenesis are the deposition of amyloid beta (Aβ) plaques and tau protein neurofibrillary tangles, particularly in the hippocampus [2,3].

AD-associated amyloid plaques contain amyloid beta peptides, a protein consisting of 36-43 amino acids that is generated when the amyloid precursor protein (APP) is sequentially cleaved by beta and gamma secretases [4,5]. One of the core proteins of the gamma secretase complex is the presenilin protein (PSEN); familial mutations in the PSEN1 gene have been associated with increased Aβ production [6]. Aβ40 and Aβ42 are the two most common cleaved peptides that are generated; whereas Aβ40 is the most abundant overall, Aβ42 is believed to configure the bulk of the AD amyloid plaque formation and to be the main contributor to neuronal toxicity and neuropathology [7,8]. Importantly, recent scientific evidence suggests that soluble oligomeric forms of Aβ may drive AD neuropathology to a greater extent than the more conspicuous plaque-forming insoluble fibrils [9–11].

A growing body of scientific evidence suggests that gut dysbiosis may play an important role in the development of age-related neurodegenerative disorders including AD [12–15], a phenomenon referred to as the ‘gut-brain axis hypothesis’ [16,17]. This hypothesis, which has become a matter of growing scientific interest in the field, proposes that endogenously produced gut metabolites are able to modulate a myriad of biological processes fundamental for neuronal homeostasis. One such metabolite is urolithin A (UA). UA is produced in the colon when gut bacteria break down ellagitannins, natural compounds which are found in edible plants such as pomegranates, strawberries and walnuts [18]. Numerous studies have shown that UA robustly improves mitochondrial activity, muscle function, lifespan and cognition in several animal models [19–21]. Importantly, the metabolite has been shown to be safe for oral administration in clinical trial in aging humans, where it was shown to preserve muscle health [22,23].

Neurons have high energetic demands that rely on the preservation of mitochondrial homeostasis, which requires functional mitophagy and mitochondrial remodeling [24]. Mitophagy consists of the selective degradation of mitochondria by the autophagic machinery [25], tightly linking the two biological processes, mitophagy and the broader macroautophagy. Whereas recent studies have strongly suggested mitophagy induction as underlying the beneficial effects of UA [19–22,26], questions remain regarding UA’s involvement in lysosome-mediated clearance of substrates beyond mitochondria including of characteristic neurotoxic protein species.

In our study, we evaluated cognitive function in 12-to-13-month-old female 3xTg-AD mice and the impact of UA dietary intervention on observed deficits. For this purpose, we used a battery of behavioral tests in order to assess spatial learning and memory, associative learning, willingness to explore, locomotor activity and working memory. Here we report that the compound reduced Aβ burden and enhanced cognition in the 3xTg-AD mice. UA was also able to increase lifespan in normal aging wild-type mice and to enhance autophagic Aβ clearance in neuronal cell types in culture.

Reagents and antibodies

Urolithin A was purchased from Cayman Chemical Company (#22607). Bafilomycin-A1 (#B1793) and anti-p62/SQSTM1 antibody (#P0067) were purchased from Sigma-Aldrich. Anti-amyloid beta peptide (MOAB-2) was purchased from Millipore (#MABN254). AT8 Phospho-Tau (Ser202, Thr205) was purchased from Thermo Fisher Scientific (#MN1020). Anti-β-Amyloid (6E10) (#803017) was purchased from Biolegend. LC3 antibody was purchased from Proteintech (#14600-1-AP). Actin antibody was purchased from Cell Signaling Technology (#3700) Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488 was purchased from Sigma-Aldrich (#A-11001). DMEM/F12 (#11330032) and DQ-BSA red (#D12051) were purchased from Thermo Fisher Scientific. Earl’s Balanced Salt Solution (EBSS) (#24010-043) was purchased from Gibco. DMEM (#10-013-CV), fetal bovine serum (#35-010-CV) and Penicillin-Streptomycin Solution (#30-002-CI) were purchased from Corning. Beta Amyloid oligomers were generated according to the manufacturer’s instructions using the Beta Amyloid (1-42), Aggregation Kit (#A-1170-2) purchased from rPeptide. Artwork was created using ImageJ, Graphpad Prism 7 and Illustrator.

Animals and treatment

All mice husbandry and experimental procedures were practiced in accordance to regulations approved by the Institutional Animal Care and Use Committee (IACUC).

Female 3xTg-AD [Tg(APPSwe,tauP301L)1Lfa Psen1 /Mmjax] (#034830) [29] transgenic mice, female B6129SF2/J (#101045) and male C57BL/6NJ (#005304) wild-type mice were purchased from the Jackson Laboratory. Starting at 3 months of age and until the noted experimental endpoints, mice were fed regular chow or chow supplemented with 25 mg/kg of UA in alternate weeks (one week on, one week off). Food pellets were purchased from Dyets (#AIN-93G) and UA from Cayman Chemical Company (#22607). All animals had free access to food and water. 3xTg mice or control B6129SF2/J mice were used for behavioral analysis at 12-13 months of age and then euthanized for biochemical and neuropathological analysis.

Immunofluorescence of mouse brain tissue

Anesthesized mice were perfused with 1x PBS and whole brains were sagittally bisected. Left hemispheres were placed in 4% PFA for 48 hours, then washed in cold TBS and cut using a Leica VT 1000S Vibratome. 50-µm coronal sections were obtained and stored in cryogenic buffer (0.1 M potassium acetate,40% ethylene glycol, and 1% polyvinyl pyrrolidone) at -20 degrees. Free-floating sections showcasing the rostral hippocampus were subject to epitope unmasking in 88% formic acid for 3 minutes, then transferred to 500 µL citrate buffer (0.01M, 6.0 pH) and microwaved 3 x 5 seconds at 100% power. Sections were then washed 3 x in TBS, permeabilized for 1 hr in TBS plus 0.2% Triton X-100, blocked for 1 hr in 5% normal goat serum in TBS 0.2% Triton X-100 permeabilization buffer for 1 hr. Subsequently, sections were incubated in blocking buffer at 4°C overnight with anti-amyloid beta peptide antibody (MOAB-2) (1:200) or at room temperature overnight with anti-phospho-Tau AT8 (1:50). Sections were washed 3 x with TBS plus 0.1% Tween-20 for 1 hr and incubated in TBS, 0.1% Tween-20, 5% NGS, and goat anti-mouse IgG (H+L) secondary antibody, Alexa Fluor™ 488 (1:500). After 3 additional washes with TBS plus 0.1% Tween-20, sections were mounted on glass slides with ProLong Gold plus DAPI (ThermoFisher, #P36931).

ELISA

Anesthesized mice were perfused with 1x PBS and whole brains were sagittally bisected. Right hemispheres were further dissected to separate hippocampus and cortex for downstream ELISA analysis. Hippocampal and cortical tissues were homogenized in lysis buffer (50mM Tris, 150mM NaCl, 1% NP40), supplemented with proteases and phosphatase inhibitors (Roche). Homogenized samples were sonicated with probe sonicator on ice for 30 sec at low level, then were centrifuged at 20,000g for 30 min at 4°C. Pellets obtained upon centrifugation were washed once with PBS, then resuspended in ice-cold 70% formic acid for measurement of insoluble Aβ by ELISA. Formic acid neutralization buffer (1M Tris base, 0.5 M Na2HPO4, 0.05% NaN3) was used to adjust for pH prior to any downstream assays. Protein levels in both fractions were normalized to the protein concentration determined via Bradford Protein Assay. Insoluble Aβ was measured using Invitrogen Aβ42 Human ELISA Kit (#KHB3441) according to the manufacturer’s instructions. Briefly, neutralized insoluble fractions of brain tissue homogenates were loaded into precoated, flat bottom 96-well plates and to this Aβ42 Detection Antibody solution was added. The mixture was incubated at room temperature for 3 hrs with gentle shaking. The plates were then thoroughly washed with the supplied 1X Wash Buffer before Anti-Rabbit IgG HRP was added and incubated at room temperature for 30 min. After thoroughly washing the wells with supplied 1X Wash Buffer, Stabilized Chromogen was added to each well, following by 30 min incubation at room temperature in the dark. Stop solution was added and the absorbance was measured at 450 nm using a Cytation3 plate reader. The concentration of Aβ42 (picograms per milliliter of sample) detected in the insoluble fraction was used for statistical analysis.

Morris Water Maze

MWM is a circular container (122 cm diameter; 50 cm high) filled with water (22 ± 1ºC) made opaque with non-toxic white paint. Four soft walls, each containing a visual cue consisting of four drawings with distinct shapes and bright colors, surrounded the container. Animals were acclimatized in advance to the experimentation room. Each trial was 60 s in duration. The first training trial involved placing the mouse in an enclosed rectangular channel (15 cm x 122 cm) running across the diameter of the container with a hidden platform (15 cm x 15 cm) that is 1.5 cm below the opaque water surface in the center of the channel. During subsequent training trials no guiding channel was utilized, the hidden platform was located in a fixed quadrant and the animal drop location was randomized. The entire pool training procedure with hidden platform and random drop location included 4 trials per day over a 4 day period, 24 hours and 72 hours after the last training trial, probe trials were performed in the absence of a hidden platform. In the probe trial, time spent in the platform quadrant (quadrant where the hidden platform was previously located) was measured and the number of times that the mice crossed the original platform location. Ethovision XT (Noldus Information Technology) software was used to record mice movements during trials.

Cued fear conditioning

During the cued fear conditioning memory task, a light and tone conditioned stimulus is paired with an electric shock as unconditioned stimulus. An electric shock induces fear in the mice that is measurable as freezing behavior. The assay was performed in four computer-controlled chambers (28 x 21 x 22 cm) (Med Associates) as previously described [72]. The floor of each chamber had stainless steel rods connected to a shock scrambler and generator. During day 1 or training day, the mice were subject to 2 minutes of white noise of 70 dB, followed by 30 seconds with a light and sound tone stimulus. The last 2 seconds of the light and tone stimulus (conditioned stimulus) were paired with an electric shock (unconditioned stimulus) of 0.45 mA. Following, mice were subject to another 2 minutes of white tone, 30 seconds of conditioned stimulus, 2 seconds of conditioned and unconditioned stimulus and 2 minutes of white noise. During day 2 or test day, the same program of day 1 was repeated minus the unconditioned stimulus (no electric shock). This assay allowed us to assess the ability of the mice to pair the conditioned stimulus to the electric shock. Freezing behavior was recorded for all mice and the fold change of freezing behavior during the test day (day 2) between the first conditioned stimulus time and the previous 2 minutes of white noise baseline was calculated.

Elevated Plus Maze

The elevated plus maze consists of two open arms (without walls, 38 x 5 cm wide) and two closed arms (with walls 16 cm tall), the intersection of the arms is 5 x 5 cm wide, and the entire maze is elevated 77 cm above the ground (Hamilton-Kinder, Poway, CA). Mice were first allowed to acclimatize to the testing room for one hour. During the test, mice were placed at the intersection between open and closed arms and were allowed to freely explore for 10 minutes. We assessed the exploratory behavior of the experimental mice at the elevated plus maze task by recording the time in which the center of the mouse body was located in the intersection area while the mouse dipped its head outside the open arms area.

Y-Maze

The Y-maze consisted of three 40 x 8 x 15 cm arms. Mice were first allowed to acclimatize to the testing room for one hour. Each mouse was placed at the end of one arm, then allowed to move freely for 10 min. Total distance traveled and arm entries were monitored with the EthoVision video-tracking system.

Cell culture

The HT-22 mouse hippocampal neuronal cell line (#SCC129, Millipore) and SH-SY5Y human neuroblastoma cell line (#CRL-2266, ATCC) were used in this study. HT-22 cells were grown in DMEM medium, SH-SY5Y cells were grown in 1:1 DMEM/F-12. All medium was supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. All cells were grown at 37ºC and 5% CO2 and cultures were passaged with fresh medium two to three times per week.

Real-time quantitative PCR for gene expression analysis

Quick-RNA MiniPrep Kit purchased from Zymo Research (#11-328) was used for total RNA extraction. The cDNA was generated according to the manufacturer’s instructions with High-Capacity cDNA Reverse Transcription Kit purchased from Thermo Fisher Scientific (#4368814). Primers for RT-qPCR were designed using NCBI Primer BLAST (Table S1), and RT-qPCR performed with LightCycler 480 SYBR Green I Master purchased from Roche (#04707516001) using a LightCycler 480 Instrument II from Roche. The RT-qPCR reactions were performed using 10 ng/μL cDNA per reaction in technical triplicates and the fold change in gene expression was calculated with the 2(-Delta Delta C(T)) method [73], normalized to the gene expression of human β-actin (ACTB) or mouse glyceraldehyde-3-phosphate dehydrogenase (Gadph).

DQ-BSA red

Mouse hippocampal HT22 cells were seeded in 8-well chamber slides at 15,000 cells per well. After 24 hours, cells were incubated for 6 hours in EBSS medium containing 10 mg/ml of DQ-BSA red dye, supplemented with 30 μM of UA or vehicle and/or 50 μM of bafilomycin. Cells were then fixed with 4% PFA prepared in PBS for 15 minutes, washed three times with PBS, permeabilized for 10 minutes in PBS plus 0.1% Triton X-100 and mounted with ProLong Gold plus DAPI (ThermoFisher, #P36931).

Protein extraction and immunoblotting

For total protein extraction, cells were cultured in 12-well plates and lysed in cell lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl pH 8.0, cOmplete EDTA-free Protease Inhibitor Cocktail (#11836170001) and PhosSTOP phosphatase inhibitor tablets (#PHOSS-RO) purchased from Roche), sonicated (15 cycles: 15 seconds on, 30 off) with a Diagenode Bioruptor sonication system at 4^o C, and then centrifuged 20 min at 15000 g. The supernatants were collected and boiled at 95°C for 5 minutes with sample buffer (0.25M Tris-HCl pH 6.8, 50% glycerol, 5% SDS, 0.05% bromophenol blue and 10% 2-mercaptoethanol. The samples were then run on 4-12% gradient glycine gels (#NP0321BOX) or 16% tricine gels (#EC6695BOX) purchased from Thermo Fisher Scientific and blotted onto a 0.2 μm PVDF membrane purchased from Millipore (#ISEQ00010). The membranes were blocked with 3% BSA in PBS-T (0.1% Tween 20 in PBS) for 1 hour at room temperature, and then stained overnight at 4°C with 3% BSA in PBS-T and the primary antibodies referenced above. Membranes were washed with PBS-T and stained for 1 hour at room temperature with fluorescent secondary antibodies: anti-mouse IgG(H+L) DyLight 800 conjugate (#5257, CST) and anti-rabbit IgG(H+L) DyLight 680 conjugate (#5366, CST). The images were captured using a LiCor Odyssey Infrared Imaging System 9120 (LI-COR Biosciences).

Urolithin A reduces Aβ burden in 3xTg-AD mice

Previous studies have demonstrated that UA can act as a potent inducer of mitophagy [19,20,22], capable of ameliorating dysfunctional mitochondrial function in both an Aβ42 Caenorhabditis (C.) elegans model and the APP/PS1 mouse model of AD [21,27]. Here, we explored the effects of UA dietary supplementation on the age-dependent progression of Aβ pathology in 3xTg‐AD mice. 3xTg-AD mice are a useful model of late-onset AD (LOAD) as they display several cardinal phenotypes of the human disease including age-related accumulation of Aβ and phosphorylated Tau species, gliosis and eventual neuronal loss, accompanied by progressive cognitive deficits [28,29]. Female mice were used for these as they have been reported to display earlier and more consistent Aβ pathology than that observed in males [30]. Immunocytochemistry was performed using an Aβ-human-specific monoclonal antibody (MOAB-2, n = 9 per experimental group). Hippocampal sections from left hemibrains were −2.2 mm caudal to bregma, representing sections of the rostral hippocampus. Extracellular plaques were detected in the CA1 and subicular regions of the rostral hippocampus in 14 out of 18 3xTg animals. In contrast, no immunoreactive plaques were found in age-matched wild-type mice (Fig. S1a). Quantitative analysis of Aβ immunoreactivity in sections obtained from 3xTg-AD animals revealed that overall plaque burden was reduced in mice fed the UA-supplemented diet (unpaired t-test analysis, p-value = 0.0202; Fig. 1a).

We performed additional Aβ42 quantification in hippocampal and cortical homogenates via sandwich ELISA using an antibody specific for this species (6E10). Unpaired t-test analysis revealed a trend toward decreased hippocampal Aβ in UA-fed animals (unpaired t-test analysis, p-value = 0.0577; Fig. 1b) and a statistically significant decrease in cortical Aβ in UA-fed animals (unpaired t-test analysis, p-value = 0.0199; Fig. 1b).

We next proceeded to measure phospho-tau immunoreactivity in these same sections. For this purpose, we utilized the AT8 antibody specific to phosphorylated Ser202 and Thr205 residues. Whereas no immunoreactivity was detected in the sections extracted from wild-type mice (Fig. S1a), specific staining pertaining to phospho-tau was observed in a number but not all 3xTg mice (Fig. S1b). Due to the inconsistency in phospho-tau immunoreactivity across the experimental subjects examined, we were not able to determine the statistical impact of UA on this marker of tau pathology at this time point.

Urolithin A reverses spatial learning and memory deficits in 3xTg mice

Previous studies have demonstrated that UA is neuroprotective and can rescue cognitive deficits in the APP/PS1 mouse model [21,27]. We evaluated spatial memory using the well-established Morris Water Maze (MWM) [31,32] in 13-month-old female mice. The test involves a 4-day learning period followed by two probe trials 24 hours and 72 hours after the last learning session. During each learning trial, time spent in the platform quadrant and escape latency were recorded (the latter defined as time needed to find the platform). During the probe trials, time spent in the platform quadrant and the number of platform crossings were recorded (the latter defined as number of instances of swimming over the area where the platform used to be in the previous learning trials). 3xTg mice (3xTg/CTRL) spent less time than wild-type mice (WT/CTRL) in the platform quadrant during the training period (Fig. 2a) and required a significantly longer time to find the platform (Fig. 2b). In a manner similar to wild type, UA-fed 3xTg mice (3xTg/UA) spent significantly more time in the platform quadrant (Fig. 2a) and required significantly less time to find the platform than the 3xTg/CTRL (Fig. 2b). During the first probe trial, no group among the four experimental groups (WT/CTRL, WT/UA, 3xTg/CTRL and 3xTg/UA) showed any significant difference in the time spent in the target quadrant (where the platform formally resided) (Fig. 2c). In the second probe trial there was a trend (p-value = 0.099) for the 3xTg/CTRL to spend less time in the target quadrant as compared to the WT/CTRL (Fig. 2c). Similarly, the number of platform crossings for 3xTg/CTRL did not significantly differ from the other experimental groups during the first probe trial (Fig. 2d) but during the second probe trial 3xTg/CTRL crossed the target a significantly reduced number of times compared to WT/CTRL (Fig. 2d). Importantly, 3xTg/UA mice did not demonstrate a similar significant decrease in the number of platform crossings during the second probe trial, suggesting that UA feeding improved spatial learning of the 3xTg mice. To summarize these findings, 13-month-old 3xTg-AD mice display significant deficits in spatial learning and memory that are successfully reversed by UA diet supplementation, suggesting a positive effect on cognition, likely linked to the observed reduction in neuropathology (Fig. 1).

Urolithin A ameliorates associative learning and exploratory behavior in 3xTg mice

In order to assess associative learning ability in 3xTg-AD mice, we performed a cued fear learning task, whereby mice learn to associate visual and auditory cues with an electric shock and display a freezing behavior upon presentation of the cues [33]. 12-month-old WT/CTRL, WT/UA and 3xTg/UA displayed significantly increased freezing behavior upon cues (Fig. 3a). In contrast, 3xTg/CTRL increased their freezing behavior upon these cues to a lesser extent, not statistically significant, indicative of deficits in associative learning (Fig. 3a).

We used the elevated plus maze to measure the number of times a mouse located in the center of the maze would dip its head below the level of the maze in the open arm, a behavior that can indicate willingness to explore the surroundings [34]. We found that the 12-month-old 3xTg/CTRL performed significantly fewer head dips than age-matched WT/CTRL and 3xTg/UA (Fig. 3b).

Locomotor activity and willingness to explore were also measured using the Y-maze task [35]. 12-month-old 3xTg-AD mice, regardless of diet, displayed reduced locomotion and, reduced exploratory behavior in the Y-maze (Fig. 3c).

Additionally, we used the Y-maze to assess whether the 3xTg mice displayed any deficits in working memory as measured by the percentage of spontaneous alternations amongst all the arm alternation triads performed by each mouse. We did not observe a statistically significant change in the spontaneous alternation behavior percentage across any experimental groups (Fig. S2a). In contrast, we measured a significantly reduced number of arm entries in both 3xTg/CTRL and 3xTg/UA (Fig. S2b). Arising from the observation that a mouse may explore the same arm back and forth without making additional arm entries, we decided to analyze the number of spontaneous alternations triads normalized by distance traveled. Here, we observed that there is a trend toward a decrease in the number of spontaneous alternations performed per distance traveled in the 3xTg/CTRL, which is less pronounced in the 3xTg/UA (Fig. S2c). Significance was likely reduced by a large degree in variability in behavior within each experimental group and the marked reduction in locomotor activity displayed by the 3xTg-AD mice.

Hippocampal Aβ burden positively correlates with spatial learning and memory in control-fed but not in UA-fed 3xTg mice

Aberrant accumulation of Aβ is a cardinal sign of AD and has been robustly associated with neuropathology and cognitive deficits in humans and in animal models. As previously noted, UA diet supplementation resulted in decreased hippocampal Aβ burden in the 3xTg-AD mice and significantly reversed cognitive deficits associated with this mouse model. Based on these observations, we analyzed whether hippocampal Aβ protein levels impacted spatial learning and memory performance in the MWM at the level of the individual animal. When we plotted the hippocampal Aβ-immunoreactive pixel count in 3xTg-AD mice against both the escape latency and the number of platform crossings; we found that while Aβ protein levels did not correlate with escape latency, they were positively correlated with the number of platform crossings (r = 0.5178, p-value = 0.0277) (Fig. 4a). Next, we performed correlation analyses between Aβ42 abundance in triton-insoluble/formic acid-soluble cortical and hippocampal homogenates and escape latency and, similarly, no correlation was found between Aβ42 abundance in cortical or hippocampal homogenates and escape latency in all 3xTg-AD subjects (Fig. S3a). We then further dissected these analyses, splitting the two 3xTg-AD experimental groups according to their diet. Interestingly, there was a strong negative correlation between hippocampal Aβ plaque burden and escape latency (r = -0.6674, p-value = 0.049) and a strong positive correlation between hippocampal Aβ burden and number of platform crossings (r = 0.87, p-value = 0.0023) in the 3xTg/CTRL (Fig. 4b). In line with this, a trend toward a negative correlation was found between escape latency and Aβ42 in the hippocampus homogenates of the 3xTg/CTRL subjects (r = -0,693, p-value = 0.0567) (Fig. S3b). In stark contrast, in the 3xTg/UA mice, the correlation between hippocampal Aβ plaque burden and escape latency or number of platform crossings was weaker and not statistically significant (Fig. 4c). Additionally, a significant positive correlation was observed between escape latency and Aβ42 in the cortical (r = 0.6887, p-value = 0.0489) and hippocampal homogenates (r = 0.7849, p-value = 0.021) of the 3xTg/UA mice (Fig. S3c).

To summarize our findings on the correlation between Aβ burden and spatial learning and memory, we found that in the control diet-fed 3xTg-AD mice (Fig. 4b), higher amount of Aβ extracellular plaques in the hippocampus was associated with more intact spatial learning and memory. In contrast, in 3xTg/UA mice (where plaque burden is significantly lower than it is in 3xTg/CTRL mice) both cortical and hippocampal Aβ42 abundance correlated with reduced spatial learning and memory. These findings suggest that extraneuronal Aβ plaque formation may be a protective mechanism that mitigates pathology associated with accumulation of Aβ, which if allowed to accumulate would otherwise perturb spatial learning and memory.

UA extends median survival in male C57BL/6 mice

Mitophagy and autophagy are cellular processes known to be implicated in aging and lifespan [36,37]. Disruptions in this cellular process have been associated with reduced lifespan across various species, including vertebrates [38–41]. Following our observations that UA can reduce Aβ abundance in the brain of 3xTg-AD mice and reverse associated cognitive deficits, we investigated whether long-term intermittent administration of the compound would be able to enhance lifespan in normal aging mice. For this purpose, we fed UA on alternate weeks (one week on, one week off) to a cohort of male C57BL/6 mice starting at 3 months of age. We found that dietary supplementation of UA significantly increased survival (Fig. 5). The median lifespan at 80^th percentile mortality was extended 1 8.75% from the UA feeding start point (Log-rank test: chi square = 5.068, p-value = 0.0244).

UA induces the expression of autophagy-related genes, increases autophagy flux and clears Aβ in neuronal cells in vitro

Increased expression of mitophagy-related genes and proteins have been observed following UA administration in both C. elegans and in mouse muscle cells and tissues [20,26]. Given the ability of UA to mitigate neuropathology in the 3xTg-AD mouse model, we looked at the impact of UA in more tractable neuronal cell culture models to determine whether its effects could be elicited by enhanced macroautophagy and subsequent removal of Aβ. For this purpose, we utilized mouse hippocampal cells and SH-SY5Y human neuroblastoma cells in order to determine whether UA can modulate endosomal biogenesis and the autophagy pathway. We performed gene expression and western blot studies and found that UA induces the expression of a panel of autophagy-related genes in both murine and human neuronal cell types (Fig. 6a). Western blot analysis of human neuroblastoma cell lysates showed that 30 μM UA for 24 hours caused a marked decrease in protein levels of Sequestosome-1 (SQSTM1) and Microtubule-associated protein light chain 3 (LC3) upon UA treatment (Fig. S4). Decreased expression of both proteins is a well-established readout of autophagy flux, indicating their effective clearance by degradative autophagosomes [42]. Next, we assessed whether UA’s role at inducing autophagy-related gene expression and autophagosomal degradation was preceded by increased endosomal acidification suggestive of enhanced autophagic capacity [43,44]. Using DQ-BSA self-quenching staining which emits bright fluorescence upon its fragmentation in functional acidic endosomes [45], we found that UA significantly increased DQ-BSA fluorescence in mouse hippocampal cells after 6 hours of treatment (Fig. 6b).

Following the observations that UA can enhance the turnover of the endolysosomal pathway and autophagy, we decided to perform an in vitro assessment of UA’s ability to augment the clearance of exogenous Aβ oligomers. We treated mouse hippocampal cells with Aβ oligomers for 48 hours in the presence or absence of UA co-treatment. In cells treated with UA, Aβ is less abundant after 48 hours, suggesting that UA’s ability to upregulate autophagy leads to improved clearance of the exogenous Aβ species (Fig. 6c). Simultaneous treatment of mouse hippocampal cells with UA and an inhibitor of autophagy, bafilomycin, partially reverses the clearance of Aβ. In parallel, levels of SQSTM1 and LC3 proteins, as a read-out of autophagic flux, were found to be decreased in cells treated with UA. In contrast, co-treatment with bafilomycin to block autophagosomal acidification and degradation reversed the depletion of both autophagy-related proteins (Fig. 6c).

Collectively, these data suggest that UA can effectively increase autophagic function in neuronal cell types in a mechanism that involves the upregulation of autophagy-related gene expression, increased numbers of acidic endosomes and enhanced clearance of autophagosomes as measured by a marked decrease in the protein levels of LC3 and SQSTM1. Additionally, exogenous addition of Aβ oligomers to mouse hippocampal cells leads to detection of Aβ proteins in the lysates. Aβ abundance decreased following UA treatment in an autophagy-dependent manner, as pharmacologically inhibiting autophagosomal acidification led to abrogation of UA-mediated Aβ clearance.

Biomedical research is increasingly demonstrating an association between defective lysosomal function and various pathological processes in humans, including inherited lysosomal storage disorders [46], cancer [47–49] and neurodegeneration [50–52]. Autophagic dysfunction is a commonly observed pathological feature in neurodegeneration associated with both transgenic animal models and human AD patients [53–56]. In AD, accumulation of lysosomes and subsequent blockage of lysosomal function has been described as a cause for disrupted axonal vesicle transport and axonal dystrophy [57]. Therefore, modulation of the autophagic process and the development of therapeutics to that effect are of general interest, not only in AD, but also other neurodegenerative disorders including Huntington’s and Parkinson’s disease [58, 59].

UA is a benzo-coumarin produced by the human gut microbiota. It has been gathering significant attention due to its mitophagy-inducing properties, which are thought to drive its beneficial health effects in muscle and in the central nervous system across several species and disease models. In our study, we utilized the 3xTg-AD mouse model to uncover potential therapeutic benefits of UA in the context of AD-associated pathology. The 3xTg-AD mouse model is highly regarded as a late onset Alzheimer’s disease (LOAD) model, as it displays progressive neuropathology and behavioral and cognitive impairment with age [29, 58]. The 3xTg model displays sex differences, with increased Aβ levels and more extensive cognitive deficits being reported in female mice [28, 30]. A sex-bias featuring enhanced pathology in females has also been observed in another commonly used mouse model of AD, the 5xFAD-AD model. AD is also found to be more prevalent in women. For this reason, we chose to conduct our study using female mice only. Importantly, genetic drift has been documented in the 3xTg-AD model such that, compared to original findings, there is now a delay in the presentation of its neuropathological hallmarks and associated neurodegeneration, and this delay is particularly pronounced in males [28, 59]. This is likely the reason that while we were able to detect extensive amyloidosis at 13-months of age in this model, particularly in the hippocampus, we did not detect the same level of tauopathy at this same time point. Nonetheless, deficits in spatial learning, associative learning, exploratory behavior and locomotion were apparent at this pathological stage.

Administration of UA starting at 3 months of age for a period of 10 months was found to effectively reduce Aβ plaque burden in the hippocampus and Aβ42 abundance in hippocampal and cortical homogenates. Our findings are in line with a previous study that showed a decrease in Aβ plaque formation in the hippocampus of APP/PS1 mice following UA administration [21]. In 13-month-old female 3xTg-AD mice, Aβ40/42 positive plaques were predominant in the hippocampus and absent from the neocortex, whereas Aβ42 concentration in hippocampus homogenates was 40 to 50 times more abundant than in the neocortex. Following UA administration, we observed a significant reduction in Aβ-positive plaque load in the hippocampus and in Aβ42 in cortical homogenates, as well as a trend toward a reduction of Aβ42 in hippocampal homogenates. In order to explain the differences we observed between reductions in Aβ-positive plaques and Aβ42 in hippocampal homogenates, we must take into account differences in expression of Aβ40 and Aβ42 and whether these proteins were localized intracellularly or present in the dense extracellular plaques. We found high variability of Aβ burden across subjects suggesting that within the same 3xT-AD genotype, some animals display high Aβ burden and others have significantly lower cerebral Aβ expression. Within the UA diet experimental group, there may additionally be variability in response to UA treatment. We determined that while behavioral performance is highly variable at the 12-13-month time point between individual animals, overall 3xTg mice display marked deficits in spatial learning and memory, associative learning and exploratory behavior. Further, we showed that age-related cognitive decline could be reversed by UA diet supplementation.

Intriguingly, our correlation analyses showed that hippocampal Aβ plaque load positively correlated with superior spatial learning and memory in individual 3xTg-AD mice fed normal diet, but not in those on the UA-diet. Increased Aβ immunoreactivity and extensive plaque formation has also been found in clinically healthy patients [60–62], whereas neuronal loss poorly correlated with plaque formation in AD patients [63, 64]. As discussed by other groups, confinement of Aβ deposition within dense confined regions of the hippocampus may be a key protective mechanism that blunts intracellular Aβ-mediated neurotoxicity and neurodegeneration [65–67]. This hypothesis, and the observations that support it, should bring cautious scrutiny to study designs that aim to disrupt the formation and/or solubilize dense-core Aβ plaques, as such aims may ultimately prove ineffective or even hazardous in mitigating AD symptomology.

UA and other therapeutic agents that prove to be potent inducers of the autophagic machinery could enhance clearance of intracellular Aβ and/or boost the action of phagocytic microglia to remove smaller extracellular Aβ deposits, before the formation of dense-core plaque is required to control further neurological damage [68]. Using cortical and hippocampal homogenates, we found that in UA-treated 3xTg-AD mice (whose hippocampi show less dense-core plaque pathology than 3xTg mice on regular diet) both cortical and hippocampal Aβ42 levels correlated with poorer spatial learning and memory. In our view, this indicates that Aβ42 abundance outside of dense-core extracellular plaques might be a superior indicator of neuropathology and cognitive decline than quantification of plaque load.

We further demonstrated that UA is an effective inducer of macroautophagy in two separate neuronal cell lines. UA increased the expression of a panel of autophagy-related genes in both cell types and was effective in reducing the protein levels of LC3 and SQSTM1, two well-established readouts of autophagy that are acutely depleted upon increased autophagosomal degradation [42]. In Western blot analyses, LC3 resolves as a doublet of the upper band LC3-I, and the lower band LC3-II. When the autophagic process is initiated, a phosphatidylethanolamine group is added to LC3-I, causing its conversion to LC3-II [69]. Of note, in human neuroblastoma cells the expression of non-phospholipidated LC3-I is high and UA treatment enhances its conversion to LC3-II in tandem with a reduction in overall LC3 levels. In contrast, in mouse hippocampal cells lipidated LC3-II is predominant and UA treatment significantly reduces its protein levels indicating increased autophagosomal clearance.

In addition, UA increased the abundance of autophagy-functional acidic endosomes. This is in line with previous reports that described augmented autophagy-related gene expression in UA-treated worms and muscle tissue. Our results further show that in mouse hippocampal cells treated with Aβ oligomers, UA co-treatment led to a decrease in Aβ protein levels in whole cell lysates. UA-mediated Aβ clearance was found to be dependent on autophagy, as clearance was blunted by treating the cells with bafilomycin.

Finally, in terms of its efficacy as an anti-aging agent, UA has previously been demonstrated to extend lifespan in the invertebrate nematode C. elegans [20]. In our study, we show evolutionary conservation of this anti-aging property as significant lifespan extension was observed in normal aging mice intermittently fed UA. Follow-up studies that increase the sample size and include both female and male subjects are warranted to assess the efficacy of UA, as a potential rejuvenating agent.

Our findings importantly suggest that dense extracellular Aβ plaques are not necessarily predictive of cognitive decline. Our results may speak to the ongoing and highly publicized controversies surrounding AD clinical trials, where therapeutics designed to expressly prevent plaque formation, while often efficacious in lessening plaque load, are routinely and notoriously ineffective at meeting their primary endpoint, namely preventing of slowing cognitive decline [70, 71]. We show that UA is an inducer of macroautophagy that may be useful in reducing Aβ build-up and that long-term intermittent autophagy enhancement can extend lifespan in rodents. We propose that lysosomal dysfunction could be at the core of neurodegenerative disorders where proteotoxicity manifests and that modulating autophagy may prove to be a successful therapeutic approach at slowing the progression of AD and other age-related disorders.

Long-term intermittent dietary supplementation with UA significantly decreases Aβ abundance in the brains of the 3xTg-AD mouse model of AD and prevents cognitive deficits in this model. Intriguingly, the degree of Aβ plaque burden was found to negatively correlate with cognitive deficits. Our findings may suggest that plaque formation may be a protective mechanism against neurodegeneration and that novel therapeutics should target the processes that lead to increased generation of proteotoxic Aβ species. In normal aging mice, we found that UA significantly increases lifespan, a novel and exciting new finding for this small molecule, which has implications for its use as a geroprotector. Mechanistic analyses in neuronal cell lines demonstrate that UA is able to induce autophagy and enhance Aβ clearance, revealing UA as an attractive compound to explore in pathologies that present lysosomal and autophagic dysfunction.

Alzheimer’s disease

Urolithin a

Aβ

Amyloid beta

APP

Amyloid precursor protein

PSEN

Presenilin

Caenorhabditis

LOAD

Late-onset AD

SEM

Standard error of the mean

Formic acid

MWM

Morris Water Maze

Baseline

Light and tone

Post-shock

SQSTM1

Sequestosome-1

LC3

Microtubule-associated protein light chain 3

DMSO

Dimethylsulfoxide

Relative units

ACTB

β-actin

Gadph

Glyceraldehyde-3-phosphate dehydrogenase

IACUC

Institutional Animal Care and Use Committee

Ethics approval and consent to participate

All mice husbandry and experimental procedures were practiced in accordance to regulations approved by the Institutional Animal Care and Use Committee (IACUC).

Consent for publication

Not applicable

Availability of data and material

The data that support the findings of this study are available from the corresponding authors (JB, JKA) upon request.

Competing interests

The authors declare that they have no competing interests with the contents of this article.

Funding

This work was supported by grant RF1 AG062280 from the National Institutes of Health (JKA).

Author’s contributions

J.B. conceived, designed and performed experiments, analyzed and interpreted data, prepared figures, wrote and revised the manuscript; W.N. designed and performed experiments, analyzed and interpreted data; R.S. designed and performed experiments; A.R. performed experiments; J.K.A. conceived experiments, supervised the study and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Georgia Woods for critical comments on the manuscript. We thank past and present members of the Andersen and the Lithgow labs, with special mentions to Minna Schmidt and David Begelman.

Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2. https://doi.org/10.1101/cshperspect.a006239.
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992;42. https://doi.org/10.1212/wnl.42.3.631.
Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci 2020;23. https://doi.org/10.1038/s41593-020-0687-6.
Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc Natl Acad Sci U S A 2021;118. https://doi.org/10.1073/pnas.2102191118.
Hamley IW. The amyloid beta peptide: A chemist’s perspective. role in Alzheimer’s and fibrillization. Chem Rev 2012;112. https://doi.org/10.1021/cr3000994.
Dai MH, Zheng H, Zeng LD, Zhang Y. The genes associated with early-onset Alzheimer’s disease. Oncotarget 2018;9. https://doi.org/10.18632/oncotarget.23738.
Murphy MP, Levine H. Alzheimer’s disease and the amyloid-β peptide. J Alzheimer’s Dis 2010;19. https://doi.org/10.3233/JAD-2010-1221.
Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al. Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 2010;29. https://doi.org/10.1038/emboj.2010.211.
Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG. Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease. Front Cell Neurosci 2015;9. https://doi.org/10.3389/fncel.2015.00191.
Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: A path forward for Alzheimer’s disease immunotherapeutics. Alzheimer’s Res Ther 2014;6. https://doi.org/10.1186/alzrt272.
Li JJ, Dolios G, Wang R, Liao FF. Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal MicroRNA expression. PLoS ONE 2014;9. https://doi.org/10.1371/journal.pone.0090770.
Bell JS, Spencer JI, Yates RL, Yee SA, Jacobs BM, DeLuca GC. Invited Review: From nose to gut – the role of the microbiome in neurological disease. Neuropathol Appl Neurobiol 2019;45. https://doi.org/10.1111/nan.12520.
Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 2019;572. https://doi.org/10.1038/s41586-019-1443-5.
Jiang C, Li G, Huang P, Liu Z, Zhao B. The Gut Microbiota and Alzheimer’s Disease. J Alzheimer’s Dis 2017;58. https://doi.org/10.3233/JAD-161141.
Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflammation 2019;16. https://doi.org/10.1186/s12974-019-1494-4.
Stokes JH, Pillsbury DM. The effect on the skin of emotional and nervous states: Iii. theoretical and practical consideration of a gastro-intestinal mechanism. Arch Derm Syphilol 1930;22. https://doi.org/10.1001/archderm.1930.01440180008002.
Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 2004;558. https://doi.org/10.1113/jphysiol.2004.063388.
Cerdá B, Tomás-Barberán FA, Espín JC. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: Identification of biomarkers and individual variability. J Agric Food Chem 2005;53. https://doi.org/10.1021/jf049144d.
Qiu J, Chen Y, Zhuo J, Zhang L, Liu J, Wang B, et al. Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson’s disease model. Neuropharmacology 2022;207. https://doi.org/10.1016/j.neuropharm.2022.108963.
Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Félix AA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med 2016;22. https://doi.org/10.1038/nm.4132.
Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat Neurosci 2019;22. https://doi.org/10.1038/s41593-018-0332-9.
Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab 2019;1. https://doi.org/10.1038/s42255-019-0073-4.
D’Amico D, Andreux PA, Valdés P, Singh A, Rinsch C, Auwerx J. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends Mol Med 2021;27. https://doi.org/10.1016/j.molmed.2021.04.009.
Han S, Zhang M, Jeong YY, Margolis DJ, Cai Q. The role of mitophagy in the regulation of mitochondrial energetic status in neurons. Autophagy 2021;17. https://doi.org/10.1080/15548627.2021.1907167.
Scott SV, Klionsky DJ. Delivery of proteins and organelles to the vacuole from the cytoplasm. Curr Opin Cell Biol 1998;10. https://doi.org/10.1016/S0955-0674(98)80068-9.
Luan P, Amico DD, Andreux PA, Laurila PP, Wohlwend M, Li H, et al. Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy. Sci Transl Med 2021;13. https://doi.org/10.1126/scitranslmed.abb0319.
Gong Z, Huang J, Xu B, Ou Z, Zhang L, Lin X, et al. Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice. J Neuroinflammation 2019;16. https://doi.org/10.1186/s12974-019-1450-3.
Javonillo DI, Tran KM, Phan J, Hingco E, Kramár EA, da Cunha C, et al. Systematic Phenotyping and Characterization of the 3xTg-AD Mouse Model of Alzheimer’s Disease. Front Neurosci 2022;15. https://doi.org/10.3389/fnins.2021.785276.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s Disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction. Neuron 2003;39. https://doi.org/10.1016/S0896-6273(03)00434-3.
Dennison JL, Ricciardi NR, Lohse I, Volmar CH, Wahlestedt C. Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research. J Alzheimers Dis 2021;80. https://doi.org/10.3233/JAD-201014.
D’Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 2001;36. https://doi.org/10.1016/S0165-0173(01)00067-4.
Morris RGM. Spatial localization does not require the presence of local cues. Learn Motiv 1981;12. https://doi.org/10.1016/0023-9690(81)90020-5.
Maren S. Nuerobiology of Pavlovian fear conditioning. Annu Rev Neurosci 2001;24. https://doi.org/10.1146/annurev.neuro.24.1.897.
Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007;2. https://doi.org/10.1038/nprot.2007.44.
Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 2002;26. https://doi.org/10.1016/S0149-7634(01)00041-0.
Chen G, Kroemer G, Kepp O. Mitophagy: An Emerging Role in Aging and Age-Associated Diseases. Front Cell Dev Biol 2020;8. https://doi.org/10.3389/fcell.2020.00200.
Aman Y, Schmauck-Medina T, Hansen M, Morimoto RI, Simon AK, Bjedov I, et al. Autophagy in healthy aging and disease. Nat Aging 2021;1. https://doi.org/10.1038/s43587-021-00098-4.
Martinez-Lopez N, Athonvarangkul D, Singh R. Autophagy and aging. Adv Exp Med Biol. 2015;847:73–87. https://doi.org/10.1007/978-1-4939-2404-2_3.
Zhou B, Kreuzer J, Kumsta C, Wu L, Kamer KJ, Cedillo L, et al. Mitochondrial Permeability Uncouples Elevated Autophagy and Lifespan Extension. Cell 2019. https://doi.org/10.1016/j.cell.2019.02.013.
Blagosklonny MV. Rapalogs in cancer prevention: Anti-aging or anticancer? Cancer Biol Ther 2012;13. https://doi.org/10.4161/cbt.22859.
Ballesteros-Álvarez J, Andersen JK. mTORC2: The other mTOR in autophagy regulation. Aging Cell 2021;20. https://doi.org/10.1111/acel.13431.
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Autophagy 2021;17. https://doi.org/10.1080/15548627.2020.1797280.
Maxfield FR, Yamashiro DJ. Endosome acidification and the pathways of receptor-mediated endocytosis. Adv Exp Med Biol 1987;225. https://doi.org/10.1007/978-1-4684-5442-0_16.
Garg S, Sharma M, Ung C, Tuli A, Barral DC, Hava DL, et al. Lysosomal Trafficking, Antigen Presentation, and Microbial Killing Are Controlled by the Arf-like GTPase Arl8b. Immunity 2011;35. https://doi.org/10.1016/j.immuni.2011.06.009.
Marwaha R, Sharma M. DQ-Red BSA. Trafficking Assay in Cultured Cells to Assess Cargo Delivery to Lysosomes. BIO-PROTOCOL 2017;7. https://doi.org/10.21769/bioprotoc.2571.
Winchester B, Vellodi A, Young E. The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans, 28, 2000. https://doi.org/10.1042/bst0280150.
Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25:717–29. https://doi.org/10.1101/gad.2016111.
Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ. Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells. J Biol Chem. 2015;290:5592–605. https://doi.org/10.1074/jbc.M114.616714.
Macpherson IR, Rainero E, Mitchell LE, van den Berghe PV, Speirs C, Dozynkiewicz MA, et al. CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. J Cell Sci. 2014;127:3893–901. https://doi.org/10.1242/jcs.135947.
Caviston JP, Zajac AL, Tokito M, Holzbaur EL. Huntingtin coordinates the dynein-mediated dynamic positioning of endosomes and lysosomes. Mol Biol Cell. 2011;22:478–92. https://doi.org/10.1091/mbc.E10-03-0233.
Erie C, Sacino M, Houle L, Lu ML, Wei J. Altered lysosomal positioning affects lysosomal functions in a cellular model of Huntington’s disease. Eur J Neurosci. 2015;42:1941–51. https://doi.org/10.1111/ejn.12957.
Wen H, Zhan L, Chen S, Long L, Xu E. Rab7 may be a novel therapeutic target for neurologic diseases as a key regulator in autophagy. J Neurosci Res. 2017;95:1993–2004. https://doi.org/10.1002/jnr.24034.
Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J Neuropathol Exp Neurol 2005;64. https://doi.org/10.1093/jnen/64.2.113.
Haung Yu W, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al. Macroautophagy - A novel β-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol 2005;171. https://doi.org/10.1083/jcb.200505082.
Lie PPY, Yoo L, Goulbourne CN, Berg MJ, Stavrides P, Huo C, et al. Axonal transport of late endosomes and amphisomes is selectively modulated by local Ca2 + efflux and disrupted by PSEN1 loss of function. Sci Adv. 2022;8:eabj5716. https://doi.org/10.1126/sciadv.abj5716.
Lee J-H, Yang D-S, Goulbourne CN, Im E, Stavrides P, Pensalfini A, et al. Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nat Neurosci. 2022;25:688–701. https://doi.org/10.1038/s41593-022-01084-8.
Lee S, Sato Y, Nixon RA. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer’s-like axonal dystrophy. J Neurosci. 2011;31:7817–30. https://doi.org/10.1523/JNEUROSCI.6412-10.2011.
Belfiore R, Rodin A, Ferreira E, Velazquez R, Branca C, Caccamo A, et al. Temporal and regional progression of Alzheimer’s disease-like pathology in 3xTg-AD mice. Aging Cell 2019;18. https://doi.org/10.1111/acel.12873.
Yang JT, Wang ZJ, Cai HY, Yuan L, Hu MM, Wu MN, et al. Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer’s Disease. Neurosci Bull 2018;34. https://doi.org/10.1007/s12264-018-0268-9.
Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, et al. Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed alzheimer’s disease. Neurology 1988;38. https://doi.org/10.1212/wnl.38.11.1682.
Rodrigue KM, Kennedy KM, Devous MD, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. β-amyloid burden in healthy aging: Regional distribution and cognitive consequences. Neurology 2012;78. https://doi.org/10.1212/WNL.0b013e318245d295.
Mormino EC, Papp KV. Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer’s Disease. J Alzheimer’s Dis 2018;64. https://doi.org/10.3233/JAD-179928.
Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 1997;41. https://doi.org/10.1002/ana.410410106.
Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: Similarities and differences. Acta Neuropathol 2008;115. https://doi.org/10.1007/s00401-007-0312-8.
Rischel EB, Gejl M, Brock B, Rungby J, Gjedde A. In Alzheimer’s disease, amyloid beta accumulation is a protective mechanism that ultimately fails. Alzheimer’s Dement 2022;n/a. https://doi.org/https://doi.org/10.1002/alz.12701.
Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, et al. Reexamining Alzheimer’s disease: Evidence for a protective role for amyloid-β protein precursor and amyloid-β. J Alzheimer’s Dis 2009;18. https://doi.org/10.3233/JAD-2009-1151.
Huang Y, Happonen KE, Burrola PG, O’Connor C, Hah N, Huang L, et al. Microglia use TAM receptors to detect and engulf amyloid β plaques. Nat Immunol 2021;22. https://doi.org/10.1038/s41590-021-00913-5.
Friedrich RP, Tepper K, Rönicke R, Soom M, Westermann M, Reymann K, et al. Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity. Proc Natl Acad Sci U S A 2010;107. https://doi.org/10.1073/pnas.0904532106.
Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007;3. https://doi.org/10.4161/auto.4600.
Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for failed trials of disease-modifying treatments for alzheimer disease and their contribution in recent research. Biomedicines 2019;7. https://doi.org/10.3390/biomedicines7040097.
Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer’s Dement 2021;17. https://doi.org/10.1002/alz.12213.
Martinez-Losa M, Tracy TE, Ma K, Verret L, Clemente-Perez A, Khan AS, et al. Nav1.1-Overexpressing Interneuron Transplants Restore Brain Rhythms and Cognition in a Mouse Model of Alzheimer’s Disease. Neuron 2018;98. https://doi.org/10.1016/j.neuron.2018.02.029.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8. https://doi.org/10.1006/meth.2001.1262.

BallesterosAlvarezetal.2022Supplementalmaterial.pdf

Download PDF

Version 1

posted

You are reading this older preprint version

Read the latest preprint version →

Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease

Status:

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

Background

Methods

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Supplementary Files

Status:

Version 1